1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,240 | 1,300 | 30.12.25 | |
| 1,250 | 1,300 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Mira Pharmaceuticals genehmigt CEO-Boni inklusive Prämie für SKNY-Akquisition | 4 | Investing.com Deutsch | ||
| 20.12.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.11.25 | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 1 | Cision News | ||
| MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.25 | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | 313 | ACCESS Newswire | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| 23.10.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.10.25 | Mira Pharmaceuticals stock soars after positive pain treatment study results | 12 | Investing.com | ||
| 16.10.25 | Morning Market Movers: rYojbaba, Linkage Global, MIRA Pharmaceuticals, Fossil Group See Big Swings | 565 | AFX News | LOWELL (dpa-AFX) - At 7:45 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 16.10.25 | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain | 355 | ACCESS Newswire | Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA... ► Artikel lesen | |
| 16.10.25 | Why Mira Pharmaceuticals Shares Rose 69% After Hours? | 24 | Benzinga.com | ||
| 15.10.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 25 | SEC Filings | ||
| 30.09.25 | MIRA Pharmaceuticals schließt Übernahme von SKNY ab und stärkt Finanzposition durch 5 Millionen US-Dollar | 13 | Investing.com Deutsch | ||
| 30.09.25 | MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals | 3 | Investing.com | ||
| 30.09.25 | MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction | 305 | ACCESS Newswire | Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September... ► Artikel lesen | |
| 30.09.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09.25 | MIRA Pharmaceuticals reports positive Phase 1 results for pain drug | 7 | Investing.com | ||
| 22.09.25 | MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog | 221 | ACCESS Newswire | Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The... ► Artikel lesen | |
| 22.09.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.09.25 | MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals | 267 | ACCESS Newswire | MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,30 | -0,06 % | BIONTECH SE ADR - Eilmeldung am Abend: Jetzt wird's ernst! | ||
| EVOTEC | 5,450 | +0,26 % | Evotec-Aktie: Könnte schon bald die 0 Euro vorm Kurs stehen? | © Foto: fn SymbolbildDer Hamburger Biotech-Konzern Evotec taumelt. Die Aktie notiert noch knapp über der 5-Euro-Marke, aber nur wenige Cent vom Jahrestief entfernt. Gleichzeitig verkauft der Forschungsvorstand... ► Artikel lesen | |
| BB BIOTECH | 48,600 | -0,31 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 38,855 | +0,26 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,620 | +0,11 % | Morgen-Update: Curevac-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| AMGEN | 279,60 | -0,20 % | BMY vs AMGN: Which Biotech Stock Is More Resilient Now? | ||
| NOVAVAX | 5,792 | +0,33 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 298,50 | -0,37 % | Dividendenbekanntmachungen (31.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1702 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1802 EUR AGNC INVESTMENT CORP US00123Q1040 0... ► Artikel lesen | |
| BIOGEN | 146,60 | -2,17 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| ILLUMINA | 114,76 | +0,42 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,600 | +0,87 % | Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy | ||
| AAP IMPLANTATE | 1,290 | -3,01 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,510 | +2,03 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,266 | +1,08 % | Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? | ||
| SANGAMO THERAPEUTICS | 0,345 | -1,34 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
MIRA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-3,15 %) liegt der Kurs bei 1,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MIRA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.